Qiagen NV (QGEN) Stake Decreased by Douglas Lane & Associates LLC
Douglas Lane & Associates LLC cut its stake in Qiagen NV (NASDAQ:QGEN) by 26.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,334,522 shares of the company’s stock after selling 481,894 shares during the period. Douglas Lane & Associates LLC owned approximately 0.59% of Qiagen NV worth $38,661,000 at the end of the most recent reporting period.
Several other large investors have also modified their holdings of the company. Rehmann Capital Advisory Group acquired a new stake in shares of Qiagen NV during the third quarter valued at $208,000. Flossbach Von Storch AG increased its position in Qiagen NV by 17.5% in the third quarter. Flossbach Von Storch AG now owns 235,000 shares of the company’s stock valued at $6,470,000 after buying an additional 35,000 shares during the last quarter. Wells Fargo & Company MN increased its position in Qiagen NV by 2.8% in the third quarter. Wells Fargo & Company MN now owns 55,405 shares of the company’s stock valued at $1,520,000 after buying an additional 1,535 shares during the last quarter. Public Employees Retirement Association of Colorado increased its position in Qiagen NV by 0.4% in the third quarter. Public Employees Retirement Association of Colorado now owns 7,356 shares of the company’s stock valued at $202,000 after buying an additional 31 shares during the last quarter. Finally, First Trust Advisors LP increased its position in Qiagen NV by 1.1% in the third quarter. First Trust Advisors LP now owns 1,689,318 shares of the company’s stock valued at $46,355,000 after buying an additional 18,182 shares during the last quarter. Hedge funds and other institutional investors own 60.68% of the company’s stock.
Shares of Qiagen NV (NASDAQ:QGEN) traded up 0.07% on Friday, hitting $28.69. The stock had a trading volume of 515,161 shares. The stock has a 50 day moving average of $28.89 and a 200 day moving average of $28.55. Qiagen NV has a 12-month low of $20.71 and a 12-month high of $30.25. The firm has a market cap of $6.48 billion, a price-to-earnings ratio of 81.27 and a beta of 1.05.
Qiagen NV (NASDAQ:QGEN) last issued its quarterly earnings data on Wednesday, February 1st. The company reported $0.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.05. The company had revenue of $366.50 million for the quarter, compared to analyst estimates of $372.70 million. Qiagen NV had a return on equity of 10.01% and a net margin of 5.85%. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the company posted $0.31 earnings per share. Equities analysts predict that Qiagen NV will post $1.23 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This report was posted by Financial Market News and is the sole property of of Financial Market News. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at http://www.financial-market-news.com/qiagen-nv-qgen-stake-decreased-by-douglas-lane-associates-llc/1406208/.
Several research firms have commented on QGEN. Zacks Investment Research upgraded Qiagen NV from a “sell” rating to a “hold” rating in a report on Friday. Jefferies Group LLC restated a “hold” rating on shares of Qiagen NV in a report on Friday, February 3rd. Barclays PLC restated a “buy” rating on shares of Qiagen NV in a report on Monday, January 9th. Commerzbank Ag restated a “buy” rating on shares of Qiagen NV in a report on Wednesday, January 25th. Finally, DZ Bank AG restated a “neutral” rating on shares of Qiagen NV in a report on Monday, February 6th. Seven analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $27.00.
About Qiagen NV
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen NV (NASDAQ:QGEN).
Receive News & Ratings for Qiagen NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen NV and related companies with MarketBeat.com's FREE daily email newsletter.